Studies on a new 1,5-benzothiazepine derivative (CRD-401) VI. Effects on renal blood flow and renal function.
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001552:Benzazepines / Q000494:pharmacology*; D004110:Diltiazem / Q000494:pharmacology*; D004155:Diphenhydramine / Q000494:pharmacology; D004232:Diuretics / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000494:pharmacology; D005919:Glomerular Filtration Rate; D007668:Kidney / Q000098:blood supply* / Q000187:drug effects* / Q000502:physiology; D008297:Male; D009318:Natriuresis / Q000187:drug effects; D009399:Nephrons; D010208:Papaverine / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism; D011433:Propranolol / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D012964:Sodium / Q000378:metabolism; D013056:Spectrophotometry, Ultraviolet; D014665:Vasodilator Agents / Q000494:pharmacology
D001552:Benzazepines; D004232:Diuretics; D014665:Vasodilator Agents; D000804:Angiotensin II; D001285:Atropine; D004155:Diphenhydramine; D012964:Sodium; D011433:Propranolol; D010208:Papaverine; D004110:Diltiazem; D011188:Potassium; D004837:Epinephrine